Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPD489 augmentation study in adults with major depressive disorder and inadequate antidepressant response
2011-003006-25Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Lisdexamfetamine augmentation with Placebo augmentation (2 arms). Primary endpoint: Change in Montgomery-Asberg Depression Rating Scale total score. Started Nov 2011; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2011-003006-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003006-25.